Back to Search Start Over

Aquaporin 4 in Astrocytes is a Target for Therapy in Alzheimer's Disease

Authors :
Lan, Yu-Long
Chen, Jian-Jiao
Hu, Gang
Xu, Jun
Xiao, Ming
Li, Shao
Source :
Current Pharmaceutical Design; September 2017, Vol. 23 Issue: 33 p4948-4957, 10p
Publication Year :
2017

Abstract

Current experimental evidence points to the conclusion that aquaporin 4 (AQP4), which is an important water-channel membrane protein found in the brain, could play major roles in various brain conditions pathologically including pathogenesis of Alzheimer's disease (AD). In this paper, we review how AQP4 and altered astrocyte functions interact in AD, and provide experimental evidence highlighting the importance of this topic for the future investigations. The interactions of AQP4 are as follows: (i) AQP4 could influence astrocytic calcium signaling and potassium homeostasis. (ii) AQP4 is linked with the removal of interstitial β-amyloid and glutamate transmission. (iii) Furthermore, AQP4 modulates the reactive astrogliosis and neuroinflammation mechanisms. (iv) To add to this, AQP4 could participate in the AD pathogenesis through affecting neurotrophic factor production. It is therefore possible to identify certain functional molecules that regulate astrocyte make-up and functions. However, making crucial efforts to develop specific agents or drugs that target AQP4 function and test their therapeutic efficiency will be a breakthrough for addressing AD in that AQP4 controls the various physiological as well as pathophysiological features of astrocytes.

Details

Language :
English
ISSN :
13816128
Volume :
23
Issue :
33
Database :
Supplemental Index
Journal :
Current Pharmaceutical Design
Publication Type :
Periodical
Accession number :
ejs44480542
Full Text :
https://doi.org/10.2174/1381612823666170714144844